ALLVIREX
Eradication of HIV
Welcome
AllVirEx Inc. focuses on the eradication of HIV. Our technology aims to force HIV-infected cells out of their protective reservoirs (immune-privileged tissues) into the blood circulation, where they can be destroyed by cells of the immune system. Our research has identified a central mechanism for the retention of HIV-infected cells in reservoirs. Inspired by the discovery of this central mechanism, we have developed a powerful strategy to reverse retention and induce exit and destruction of infected cells in the periphery.
Matthias Clauss, PhD,
Bernhard Maier, PhD
Innovators. Dreamers.
AllVirEx, Inc. is an emerging company founded by research scientists at the Indiana University School of Medicine to commercialize novel biological therapeutics that have the potential to cure chronic HIV disease. The foundational intellectual property relating to our target identification strategies is protected through pending patent applications, which have been exclusively licensed to AlllVirEx Biotech by Indiana University.
HIV infecting a T cell(((NIAD public domain)
HIV RESERVOIRS AND
T CELL RETENTION
Recent research has demonstrated that a large part of the reverse transcribed HIV genome persist as extrachromosomal episomal DNA, which can explain the relatively high expression levels of accessory proteins such as Nef during latency (see our News and Views: Scientific Reports 2016). Our main goal is to develop therapeutics that interrupt HIV-induced mechanisms of lymphocyte retention and latent HIV reservoir formation. Targeting these pathways will enforce the exit of HIV-infected cells to become eradicated by HIV immunotherapy.
GET IN TOUCH
​We’re happy to hear from you. Contact us today to learn more about our business and how you can benefit from working with us.
116 11TH ST NW, Carmel, IN, 46032
3172782837